PHOENIX was a Phase 2, open-label, multi-center, US-only trial with four separate cohorts of patients with ADPKD, IgAN, T1D CKD, or FSGS. Bardoxolone methyl treatment in patients with ADPKD resulted in significant increase in kidney function as measured by eGFR at Week 12 from baseline.
- ADPKD affects approximately 400,000 people and is leading inheritable cause of kidney failure in the US.
- Bardoxolone methyl significantly improved eGFR (+9.3 mL/min/1.73 m²) from baseline in patients with ADPKD that historically declined ~4.8 mL/min/1.73 m² annually.
- Bardoxolone methyl was well-tolerated without any drug-related SAEs, changes in blood pressure, or evidence of fluid overload.